Continuous vs. Fixed 2-year Duration Immune Checkpoint Inhibitor Treatment of Patients With Non–Small Cell Lung Cancer: A Single Institution Database Analysis

Kobayashi, Hiroyoshi; Wakuda, Kazushige; Naito, Tateaki; Mamesaya, Nobuaki; Ko, Ryo; Ono, Akira; Kenmotsu, Hirotsugu; Murakami, Haruyasu; Shimizu, Tetsuo; Gon, Yasuhiro; Takahashi, Toshiaki

doi:10.1016/j.cllc.2023.06.005

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous clinical trial reported that non-small-cell lung cancer (NSCLC) patients exhibited a positive tumor response to one year of nivolumab monotherapy, and found that subjects who continued nivolumab monotherapy showed significant improvements in both PFS and OS compared to those who discontinued this monotherapy ( 30 ). Other recent retrospective studies have reported that NSCLC patients who continued for more than two years had no difference in time to treatment failure compared with those who discontinued after two years and an increase in irAE in the continued ICI group 5( 31 ). Given these past and present findings, and the currently limited alternative treatment options, we consider that continuation of ICI monotherapy for R/M ONB responders is reasonable.…”

Section: Discussionmentioning

confidence: 92%

Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma

Hoshi,

Enokida,

Tamura

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundOlfactory neuroblastoma (ONB) is a rare malignant tumor of the head and neck. Due to its rarity, standard systemic therapy for this condition has yet to be established. In particular, the use of immune checkpoint inhibitors (ICIs) for the recurrent or metastatic (R/M) ONB population remains unclear.MethodsWe retrospectively evaluated 11 patients with R/M ONB who received any systemic chemotherapy at two Japanese institutions (National Cancer Center Hospital East and Kyushu Medical Center) between January 2002 and March 2022 and analyzed outcomes by use of anti-PD-1 antibody (nivolumab or pembrolizumab) monotherapy.ResultsOf the 11 patients, 6 received ICI (ICI-containing treatment group) and the remaining 5 were treated with systemic therapy but not including ICI (ICI-non-containing treatment group). Overall survival (OS) was significantly longer in the ICI-containing group (median OS: not reached vs. 6.4 months, log-rank p-value: 0.035). The fraction of ICI systemic therapy in the entire treatment period of this group reached 85.9%. Four patients (66.7%) in the ICI-containing treatment group experienced immune-related adverse events (irAE), with grades of 1/2. No irAE of grade 3 or more was seen, and no patient required interruption or discontinuation of treatment due to toxicity.ConclusionICI monotherapy appears to be effective and to contribute to prolonged survival in R/M ONB.

show abstract

Section: Discussionmentioning

confidence: 92%

Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma

Hoshi,

Enokida,

Tamura

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Kobayashi et al reported some cases of local treatment for oligometastatic recurrence after 2 years of ICI administration. 6 Recently, the efficacy of local treatment for oligometastatic disease in advanced lung cancer has been reported. 7 , 8 However, most of these reports involved synchronous oligometastatic disease diagnosed within 6 months of the primary diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Lung squamous cell carcinoma responding to nivolumab retreatment six years after initial treatment: A case report

Kono,

Nakashima,

Tsubata

et al. 2024

Thoracic Cancer

View full text Add to dashboard Cite

A 61‐year‐old man presented to our hospital with a chief complaint of chronic cough. He was diagnosed with lung squamous cell carcinoma at clinical stage cT2aN3M1a. He received chemotherapy up to the fourth line, but both the primary tumor and lymph node metastases increased in size. Nivolumab, administered as the fifth line, resulted in a complete response (CR) that continued for 2 years and 8 months. Treatment was stopped due to the appearance of common terminology criteria for adverse events grade 1 pneumonitis. He was followed up without treatment for 3 years and 8 months, but a left supraclavicular fossa lymph node metastasis appeared. Retreatment with nivolumab was initiated, and the patient achieved CR again. One year and 6 months after retreatment, CR was maintained with nivolumab. This case represents a rare instance in which nivolumab yielded a significant response after a prolonged immune checkpoint inhibitor (ICI)‐free interval. Our experience has shown that the long‐term response to ICIs may deteriorate in the future. Therefore, retreatment with ICIs may be effective when the initial therapy is successful.

show abstract

Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study

Doi,

Matsuo,

Kishi

et al. 2024

Targ Oncol

View full text Add to dashboard Cite

Continuous vs. Fixed 2-year Duration Immune Checkpoint Inhibitor Treatment of Patients With Non–Small Cell Lung Cancer: A Single Institution Database Analysis

Cited by 4 publications

References 26 publications

Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma

Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma

Lung squamous cell carcinoma responding to nivolumab retreatment six years after initial treatment: A case report

Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study

Contact Info

Product

Resources

About